Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 46
1.
J Med Microbiol ; 68(11): 1671-1676, 2019 Nov.
Article En | MEDLINE | ID: mdl-31613204

Purpose. Human-adapted Bordetella parapertussis is one of the causative agents of whooping cough; however, there are currently no genotyping systems with high discriminatory power for this bacterial pathogen. We therefore aimed to develop a multilocus variable-number tandem repeat analysis (MLVA) for human-adapted B. parapertussis.Methodology. Four highly polymorphic variable number tandem repeat (VNTR) loci in the B. parapertussis genome were selected and amplified by multiplex PCR. MLVA was performed based on the number of tandem repeats at VNTR loci. The discriminatory power of MLVA was evaluated with three laboratory reference strains and 50 human isolates of B. parapertussis.Results. Multiplex PCR-based MLVA characterized 53 B. parapertussis reference strains and isolates into 25 MLVA types and the Simpson diversity index was 0.91 (95 % confidence interval, 0.86-0.97). The three reference strains exhibited different MLVA types. Thirty-one Japanese isolates, ten French isolates and three Taiwanese isolates belonged to fourteen, nine and three MLVA types, respectively. In contrast, all five Australian isolates belonged to the same type. Two Japanese isolates collected from patients with known epidemiological links had the same type.Conclusion. Our novel MLVA method has high discriminatory power for genotyping human B. parapertussis. Regarding this organism, this genotyping system is a promising tool for epidemiological surveillance and investigating outbreaks.


Bordetella parapertussis/genetics , Bordetella parapertussis/isolation & purification , Multilocus Sequence Typing/methods , Whooping Cough/microbiology , Bordetella parapertussis/classification , Humans , Minisatellite Repeats , Whooping Cough/diagnosis
2.
Mol Pain ; 15: 1744806918825044, 2019.
Article En | MEDLINE | ID: mdl-30799685

BACKGROUND: The glutamate type 1 transporter (GLT1) plays a major role in glutamate homeostasis in the brain. Although alterations of GLT1 activity have been linked to persistent pain, the significance of these changes is poorly understood. Focusing on the rostral ventromedial medulla, a key site in pain modulation, we examined the expression and function of GLT1 and related transcription factor kappa B-motif binding phosphoprotein (KBBP) in rats after adjuvant-induced hind paw inflammation. RESULTS: After inflammation, GLT1 and KBBP showed an early upregulation and gradual transition to downregulation that lasted throughout the eight-week observation period. Nitration of GLT1 was reduced at 30 min and increased at eight weeks after inflammation, suggesting an initial increase and later decrease in transporter activity. Mechanical hyperalgesia and paw edema exhibited an initial developing phase with peak hyperalgesia at 4 to 24 h, a subsequent attenuating phase, followed by a late persistent phase that lasted for months. The downregulation of GLT1 occurred at a time when hyperalgesia transitioned into the persistent phase. In the rostral ventromedial medulla, pharmacological block with dihydrokainic acid and RNAi of GLT1 and KBBP increased nociception and overexpression of GLT1 reversed persistent hyperalgesia. Further, the initial upregulation of GLT1 and KBBP was blocked by local anesthetic block, and pretreatment with dihydrokainic acid facilitated the development of hyperalgesia. CONCLUSIONS: These results suggest that the initial increased GLT1 activity depends on injury input and serves to dampen the development of hyperalgesia. However, later downregulation of GLT1 fosters the net descending facilitation as injury persists, leading to the emergence of persistent pain.


Afferent Pathways/metabolism , Amino Acid Transport System X-AG/metabolism , Chronic Pain/pathology , Neuroglia/metabolism , Amino Acid Transport System X-AG/genetics , Animals , Avoidance Learning , Brain Stem/physiology , Chronic Pain/chemically induced , Disease Models, Animal , Excitatory Amino Acid Transporter 1/genetics , Excitatory Amino Acid Transporter 1/metabolism , Freund's Adjuvant/toxicity , Gene Expression Regulation/drug effects , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Hyperalgesia/physiopathology , Immunoprecipitation , Male , Pain Measurement , Phosphopyruvate Hydratase/genetics , Phosphopyruvate Hydratase/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Rats , Rats, Sprague-Dawley , Transduction, Genetic
3.
Microbiol Immunol ; 61(11): 490-496, 2017 Nov.
Article En | MEDLINE | ID: mdl-28906022

Culture supernatants of Bordetella pertussis are a brilliant yellow; however, the structure and biological role of the responsible pigment have not been investigated. In this study, a brilliant yellow-colored fraction was extracted from culture supernatants of B. pertussis and analyzed by HPLC. UV-visible spectral analysis and mass spectrometry identified the brilliant yellow pigment as riboflavin. Riboflavin production was high in lag and early log phases and riboflavin was found to enhance growth of B. pertussis in low-density cultures. Riboflavin production is not regulated by the BvgAS system. In addition, it was found that other Bordetella species, such as B. parapertussis, B. holmesii and B. bronchiseptica, also release riboflavin into their culture supernatants. This is the first report that B. pertussis secrets riboflavin to the extracellular space and that riboflavin may promote its growth. The mechanism may be associated with pathogenesis of B. pertussis.


Bordetella pertussis/metabolism , Pigments, Biological/metabolism , Bordetella pertussis/chemistry , Bordetella pertussis/growth & development , Chromatography, High Pressure Liquid , Mass Spectrometry , Pigments, Biological/chemistry , Riboflavin/chemistry , Riboflavin/metabolism
4.
Sci Rep ; 7(1): 10107, 2017 08 31.
Article En | MEDLINE | ID: mdl-28860501

Systemic infusion of bone marrow stromal cells (BMSCs), a major type of multipotent stromal cells, produces pain relief (antihyperalgesia) that lasts for months. However, studies have shown that the majority of BMSCs are trapped in the lungs immediately after intravenous infusion and their survival time in the host is inconsistent with their lengthy antihyperalgesia. Here we show that long-lasting antihyperalgesia produced by BMSCs required their chemotactic factors such as CCL4 and CCR2, the integrations with the monocytes/macrophages population, and BMSC-induced monocyte CXCL1. The activation of central mu-opioid receptors related to CXCL1-CXCR2 signaling plays an important role in BMSC-produced antihyperalgesia. Our findings suggest that the maintenance of antihypergesia can be achieved by immune regulation without actual engraftment of BMSCs. In the capacity of therapeutic use of BMSCs other than structural repair and replacement, more attention should be directed to their role as immune modulators and subsequent alterations in the immune system.


Hyperalgesia/immunology , Mesenchymal Stem Cells/immunology , Pain/immunology , Animals , Chemokine CCL4/metabolism , Chemokine CXCL1/metabolism , Female , Macrophages/immunology , Male , Rats , Rats, Sprague-Dawley , Receptors, CCR2/metabolism , Receptors, Opioid, mu/metabolism , Signal Transduction
5.
Brain Res ; 1669: 89-96, 2017 Aug 15.
Article En | MEDLINE | ID: mdl-28465227

There is an urgent clinical need for an effective therapeutic agent to treat neuropathic pain. This study explored whether intrathecal administration of bovine lactoferrin (bLF), in combination with signal transduction pathway inhibition or an inflammatory cytokine production, results in reduced allodynia/hyperalgesia in the whisker pad area following mental nerve transection (MNT) in rats. Rats were intrathecally infused with bLF, lipopolysaccharide from Rhodobacter sphaeroides (LPS-RS), an antagonist of Toll-like receptor 4 (TLR4), or interleukin (IL)-18 binding protein (BP). bLF attenuated allodynia/hyperalgesia and blocked upregulation of phosphorylated (p)-p38 mitogen-activated protein kinase (MAPK), p-nuclear factor (NF)-κB p65, p-IκB kinase, and IL-18 in the trigeminal subnucleus caudalis (Vc). Microglia expressed p-p38 and astrocytes expressed p-NF-κB p65 in the Vc following MNT. LPS-RS had the same effects as bLF, except for attenuation of p-NF-κB p65. IL-18BP attenuated allodynia/hyperalgesia and IL-18 upregulation in the Vc. These results suggest that bLF suppresses IL-18 production, which is involved in allodynia/hyperalgesia following MNT, by inhibiting TLR4-derived p38 MAPK activation in microglia. Additionally, binding of bLF to tumor necrosis factor receptor-associated factor 6 might result in inhibition of p38 MAPK and NF-κB activation. The findings suggest that bLF could serve as a potent therapeutic agent for neuropathic pain.


Analgesics, Non-Narcotic/therapeutic use , Facial Pain/drug therapy , Hyperalgesia/drug therapy , Lactoferrin/pharmacology , Neuralgia/drug therapy , Trigeminal Nerve Injuries/drug therapy , Animals , Astrocytes/drug effects , Astrocytes/metabolism , Astrocytes/pathology , Cattle , Disease Models, Animal , Facial Pain/etiology , Facial Pain/metabolism , Facial Pain/pathology , Hyperalgesia/etiology , Hyperalgesia/metabolism , Hyperalgesia/pathology , Interleukin-18/metabolism , Lipopolysaccharides , Male , Microglia/drug effects , Microglia/metabolism , Microglia/pathology , Neuralgia/etiology , Neuralgia/metabolism , Neuralgia/pathology , Rats, Sprague-Dawley , Rhodobacter sphaeroides , Trigeminal Nerve Injuries/complications , Trigeminal Nerve Injuries/metabolism , Trigeminal Nerve Injuries/pathology , Vibrissae
6.
Pathog Dis ; 75(1)2017 01 01.
Article En | MEDLINE | ID: mdl-28158456

Bordetella pertussis is the etiological agent of pertussis and produces various virulence factors, including pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), most of which are positively regulated by the BvgAS two-component sensory transduction system. Here, we describe a B. pertussis isolate not expressing PT, FHA and PRN recovered from a pertussis patient. Sequencing revealed that the bvgS gene of this isolate contains a spontaneous mutation (C>A at position 955) causing the proline residue at position 319 of the BvgS protein to be substituted by threonine. Moreover, loss of PT, FHA and PRN expression was completely restored by complementation with a wild-type bvgAS locus, indicating that this non-synonymous substitution in bvgS leads to impaired BvgS function. Our findings indicate that the proline residue at position 319 in this protein plays an essential role in activation of the BvgAS system and, therefore, subsequent expression of Bvg-regulated virulence factors in B. pertussis.


Bacterial Proteins/genetics , Bordetella pertussis/physiology , Codon , Proline/genetics , Transcription Factors/genetics , Amino Acid Substitution , Bacterial Proteins/metabolism , Gene Expression Regulation, Bacterial , Humans , Mutation , Transcription Factors/metabolism , Virulence/genetics
7.
Trop Med Health ; 44(1): 28, 2016.
Article En | MEDLINE | ID: mdl-27610043

BACKGROUND: Buruli ulcer is a severe skin disease caused by Mycobacterium ulcerans. Real-time PCR targeting the IS2404 sequence has been used as a reliable and rapid method for the diagnosis of Buruli ulcer and detection of M. ulcerans in the environment. The genome of M. ulcerans contains hundreds of IS2404 copies, which have variability in certain sequences. Therefore, the design of new primers specific to conserved IS2404 regions may potentially improve the sensitivity of M. ulcerans detection and, consequently, the diagnosis of Buruli ulcer, thus ensuring timely treatment of the disease. RESULTS: In silico analysis indicates that DNA sequences of the IS2404 elements are highly variable within a single strain. As the binding sites of conventional IS2404-specific primers used for M. ulcerans detection contain polymorphic sequences, we designed new primers, which enabled the detection of M. ulcerans by real-time PCR with higher sensitivity and similar specificity with respect to that of conventional primers. However, the increase in sensitivity with the new primers depended on the M. ulcerans strain. CONCLUSIONS: The results suggest that real-time PCR based on the new primers could improve Buruli ulcer diagnosis and M. ulcerans detection in environmental samples.

8.
Microbiol Immunol ; 60(9): 599-608, 2016 Sep.
Article En | MEDLINE | ID: mdl-27515393

Bordetella holmesii is recognized as the third causative agent of pertussis (whooping cough) in addition to Bordetella pertussis and Bordetella parapertussis. Pertussis caused by B. holmesii is not rare around the world. However, to date, there is no effective vaccine against B. holmesii. We examined the protective potency of pertussis vaccines available in Japan and vaccines prepared from B. holmesii. A murine model of respiratory infection was exploited to evaluate protective potency. No Japanese commercial pertussis vaccines were effective against B. holmesii. In contrast, a wBH vaccine and an aBH vaccine prepared from B. holmesii were both protective. Passive immunization with sera from mice immunized with aBH vaccine established protection against B. holmesii, indicating that B. holmesii-specific serum antibodies might play an important role in protection. Immuno-proteomic analysis with sera from mice immunized with aBH vaccine revealed that the sera recognized a BipA-like protein of B. holmesii. An aBH vaccine prepared from a BipA-like protein-deficient mutant strain did not have a protective effect against B. holmesii. Taken together, our results suggest that the BipA-like protein plays an important role in the protective efficacy of aBH vaccine.


Bordetella pertussis/immunology , Bordetella/immunology , Cross Reactions/immunology , Pertussis Vaccine/immunology , Whooping Cough/immunology , Whooping Cough/prevention & control , Administration, Intranasal , Adoptive Transfer , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antigens, Bacterial/immunology , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/immunology , Bordetella/genetics , Bordetella pertussis/genetics , Disease Models, Animal , Epitope Mapping , Female , Immune Sera/administration & dosage , Immunization , Mice , Pertussis Vaccine/administration & dosage , Spleen/cytology , Spleen/immunology , Whooping Cough/mortality
9.
Asian Pac J Allergy Immunol ; 34(4): 314-323, 2016 Dec.
Article En | MEDLINE | ID: mdl-27543726

BACKGROUND: MF59, which is an adjuvant belonging to C30 member of the terpene family, is a T helper type-2 (Th2)-biased immune enhancer. Our previous studies showed that pyriproxyfen, a member of the terpene family with fewer carbon atoms (C20) than MF59, enhanced active T helper type-1 (Th1)-biased immune responses. OBJECTIVE: This study was performed to investigate the enhancement of antigen-specific immune responses by myrcene, a member of the terpene family with fewer carbon atoms (C10) than pyriproxyfen. METHOD: Ovalbumin (OVA) was used as an antigen to determine the effects of myrcene on the immune response. The IgG subtypes and cytokines induced by immunization of OVA with or without myrcene were monitored. Thereafter, we determined the effects of myrcene in the immune response against Ag85B, which is a dominant protective antigen for tuberculosis. RESULTS: The results showed that 0.8 mg/dose of myrcene enhanced antigen-specific total IgG immune response to OVA. Direct mixing of the antigen with myrcene was required for the enhancement of antibody production. Myrcene increased OVA-specific IgG2a titer, suggesting induction of Th1-immune response. The level of Th1 cytokines, IFN-γ was increased at 8 weeks after immunization, although IL-13 was also increased at the same time point. However, finally myrcene was found to increase Ag85B-specific total IgG titers at 5 weeks and specific IgG2a titer was increased at both 5 and 8 weeks. The results suggested that myrcene could enhance Th1 immune response. CONCLUSIONS: Myrcene enhanced specific immune responses against OVA and Ag85B. This study suggested the tendency of the enhancement of Th1 immune response by myrcene.


Adjuvants, Immunologic/pharmacology , Alkenes/pharmacology , Antibody Formation/drug effects , Monoterpenes/pharmacology , Acyclic Monoterpenes , Acyltransferases/immunology , Animals , Antigens, Bacterial/immunology , Bacterial Proteins/immunology , Enzyme-Linked Immunosorbent Assay , Female , Immunoglobulin G , Mice , Mice, Inbred BALB C , Ovalbumin/immunology , Th1 Cells/immunology
10.
PLoS One ; 11(7): e0159999, 2016.
Article En | MEDLINE | ID: mdl-27448237

Bordetella holmesii causes both invasive and respiratory diseases in humans. Although the number of cases of pertussis-like respiratory illnesses due to B. holmesii infection has increased in the last decade worldwide, little is known about the virulence factors of the organism. Here, we analyzed a B. holmesii isolate that forms large aggregates and precipitates in suspension, and subsequently demonstrated that the autoagglutinating isolate is deficient in Bordetella intermediate protein A (BipA) and that this deletion is caused by a frame-shift mutation in the bipA gene. A BipA-deficient mutant generated by homologous recombination also exhibited the autoagglutination phenotype. Moreover, the BipA mutant adhered poorly to an abiotic surface and failed to form biofilms, as did two other B. holmesii autoagglutinating strains, ATCC 51541 and ATCC 700053, which exhibit transcriptional down-regulation of bipA gene expression, indicating that autoagglutination indirectly inhibits biofilm formation. In a mouse intranasal infection model, the BipA mutant showed significantly lower levels of initial lung colonization than did the parental strain (P < 0.01), suggesting that BipA might be a critical virulence factor in B. holmesii respiratory infection. Together, our findings suggest that BipA production plays an essential role in preventing autoagglutination and indirectly promoting biofilm formation by B. holmesii.


Agglutination/genetics , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/metabolism , Biofilms , Bordetella/physiology , Agglutination Tests , Amino Acid Sequence , Animals , Bacterial Outer Membrane Proteins/chemistry , Bordetella Infections/microbiology , Gene Expression Regulation, Bacterial , Mice , Mutation , Pneumonia, Bacterial/microbiology
11.
Article En | MEDLINE | ID: mdl-26858829

BACKGROUND: Multi-drug-resistant Mycobacterium tuberculosis has been an important problem in public health around the world. However, limited information about disinfectant-susceptibility of multi-drug-resistant strain of M. tuberculosis was available. FINDINGS: We studied susceptibility of several Japanese isolates of multi-drug-resistant M. tuberculosis against disinfectants, which are commonly used in clinical and research laboratories. We selected a laboratory reference strain (H37Rv) and eight Japanese isolates, containing five drug-susceptible strains and three multi-drug-resistant strains, and determined profiles of susceptibility against eight disinfectants. The M. tuberculosis strains were distinguished into two groups by the susceptibility profile. There was no relationship between multi-drug-resistance and disinfectant-susceptibility in the M. tuberculosis strains. Cresol soap and oxydol were effective against all strains we tested, regardless of drug resistance. CONCLUSIONS: Disinfectant-resistance is independent from multi-drug-resistance in M. tuberculosis. Cresol soap and oxydol were effective against all strains we tested, regardless of drug resistance.

12.
PLoS One ; 10(9): e0137379, 2015.
Article En | MEDLINE | ID: mdl-26375454

Whooping cough due to Bordetella pertussis is increasing in incidence, in part due to accumulation of mutations which increase bacterial fitness in highly vaccinated populations. Polymorphisms in the pertussis toxin, ptxA and ptxB genes, and the pertactin, prn genes of clinical isolates of Bordetella pertussis collected in Cincinnati from 1989 through 2005 were examined. While the ptxA and prn genotypes were variable, all 48 strains had the ptxB2 genotype; ptxB1 encodes glycine at amino acid 18 of the S2 subunit of pertussis toxin, while ptxB2 encodes serine. We investigated antigenic and functional differences of PtxB1 and PtxB2. The S2 protein was not very immunogenic. Only a few vaccinated or individuals infected with B. pertussis developed antibody responses to the S2 subunit, and these sera recognized both polymorphic forms equally well. Amino acid 18 of S2 is in a glycan binding domain, and the PtxB forms displayed differences in receptor recognition and toxicity. PtxB1 bound better to the glycoprotein, fetuin, and Jurkat T cells in vitro, but the two forms were equally effective at promoting CHO cell clustering. To investigate in vivo activity of Ptx, one µg of Ptx was administered to DDY mice and blood was collected on 4 days after injection. PtxB2 was more effective at promoting lymphocytosis in mice.


Amino Acid Substitution , Pertussis Toxin/genetics , Pertussis Toxin/immunology , Polymorphism, Genetic , Alleles , Animals , Base Sequence , CHO Cells , Cricetinae , Cricetulus , Female , Humans , Mice , Models, Molecular , Pertussis Toxin/chemistry , Pertussis Toxin/toxicity , Protein Multimerization , Protein Structure, Quaternary
14.
J Infect Chemother ; 21(9): 639-46, 2015 Sep.
Article En | MEDLINE | ID: mdl-26134278

Isolation of Bordetella pertussis and detection of the pertussis genome are not always successful because of low bacterial loads in adult patients with pertussis. Antibodies against pertussis toxin (PT) are measured but have low sensitivity in vaccinated subjects. There is no reliable diagnostic method at present. In this study, a fluorescent-EIA against several pertussis antigens and genome detection were investigated to establish clinical laboratory diagnostic methods for pertussis. The study was conducted in an outpatient clinic between September 2007 and 2013. Subjects consisted of 209 patients including adults suspected of pertussis and 35 staff members of the clinic. Loop-mediated isothermal amplification (LAMP) was performed to detect the pertussis genome in 5' UTR of the pertussis toxin (PT) gene. The catalytic region of the adenylate cyclase toxin (catACT), C-terminal of filamentous hemagglutinin (cFHA), and type 3 fimbria (Fim3) were selected, which are not pertussis vaccine component. Conventional PT and FHA antibodies were examined together with type 2 fimbria (Fim2) antibodies, and these are vaccine antigens. Pertussis DNA was detected in 23 (11%) out of 209. Detection sensitivity was high in young infants. Antibodies against Fim3 showed a higher positive rate in all age groups. Staff members at the pediatric outpatient clinic showed serological booster responses in Fim2 and Fim3 antibodies more sensitively than those in PT antibodies during outbreaks. LAMP was useful for detecting the pertussis genome in young infants, whereas a serological assay for fluorescent-EIA against Fim2 and Fim3 was preferable for adolescents and adults.


Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Bordetella pertussis/immunology , Fimbriae Proteins/immunology , Virulence Factors, Bordetella/immunology , Whooping Cough/diagnosis , Whooping Cough/immunology , 5' Untranslated Regions , Adenylate Cyclase Toxin/immunology , Adhesins, Bacterial/immunology , Adolescent , Adult , Ambulatory Care Facilities , Bordetella pertussis/genetics , Catalytic Domain/immunology , Child , Child, Preschool , DNA, Bacterial/blood , Enzyme-Linked Immunosorbent Assay , Fimbriae, Bacterial/immunology , Fluorescence , Health Personnel , Humans , Infant , Middle Aged , Nucleic Acid Amplification Techniques , Pertussis Toxin/genetics , Pertussis Toxin/immunology , Whooping Cough/blood , Young Adult
15.
Vaccine ; 33(19): 2232-2239, 2015 May 05.
Article En | MEDLINE | ID: mdl-25825332

Mycobacterium ulcerans causes Buruli ulcer, a chronic and destructive necrotizing ulcer in humans. Effective vaccination should be one of the best methods for the prevention of this ulcer. However, no effective vaccines have been developed against M. ulcerans infection. In an effort to develop such a vaccine, we examined protective immunity against M. ulcerans infection in a mouse footpad-infection model. Prior infection of mice with a virulent strain of M. ulcerans or a mycolactone-deficient strain of M. ulcerans resulted in limited protection against subsequent challenge by a virulent strain of M. ulcerans. Protection was not induced in mice immunized with a formalin-treated killed whole-cell preparation of M. ulcerans. By contrast, a dewaxed whole-cell vaccine, prepared by dewaxing M. ulcerans with organic solvents that removed mycolactones and waxy cell walls from the cells, induced significant protection in mice. Our observations should facilitate development of effective vaccines against Buruli ulcer for control of this disease.


Bacterial Vaccines/immunology , Buruli Ulcer/prevention & control , Mycobacterium ulcerans/immunology , Animals , Bacterial Vaccines/administration & dosage , Bacterial Vaccines/isolation & purification , Buruli Ulcer/immunology , Buruli Ulcer/pathology , Disease Models, Animal , Female , Foot/pathology , Histocytochemistry , Mice, Inbred BALB C , Treatment Outcome
16.
Microbiol Immunol ; 57(4): 316-22, 2013 Apr.
Article En | MEDLINE | ID: mdl-23586635

Pyriproxyfen is a juvenile hormone mimic of vital importance for insect development with little risk to humans. This study was performed to investigate whether large doses of pyriproxyfen affect the immune response in mammals. Mice were immunized thrice with ovalbumin in 5% ethanol, with or without pyriproxyfen or alum. Large doses of pyriproxyfen (9 or 15 mM) significantly enhanced specific total IgG immune response. This enhancement was no longer present 24 hr after treatment with pyriproxyfen. These results suggest that pyriproxyfen is a safe chemical. Moreover, pyriproxyfen induced higher titers of IgG2a and enhanced tumor necrosis factor-alpha and gamma-interferon responses whereas alum induced IgG1 with enhanced interleukin-4 and -10. These observations indicate that the mechanism of immune enhancement by pyriproxyfen may differ from that of alum.


Immunity, Humoral/drug effects , Immunoglobulin G/immunology , Pyridines/pharmacology , Animals , Antibody Specificity/immunology , Cytokines/blood , Cytokines/immunology , Dose-Response Relationship, Drug , Female , Immunoglobulin E/blood , Immunoglobulin E/immunology , Immunoglobulin G/blood , Immunoglobulin G/classification , Mice , Ovalbumin/immunology , Pyridines/administration & dosage , Pyridines/chemistry , Time Factors
17.
PLoS One ; 8(1): e54449, 2013.
Article En | MEDLINE | ID: mdl-23372724

Tooth root formation begins after the completion of crown morphogenesis. At the end edge of the tooth crown, inner and outer enamel epithelia form Hertwig's epithelial root sheath (HERS). HERS extends along with dental follicular tissue for root formation. Ameloblastin (AMBN) is an enamel matrix protein secreted by ameloblasts and HERS derived cells. A number of enamel proteins are eliminated in root formation, except for AMBN. AMBN may be related to tooth root formation; however, its role in this process remains unclear. In this study, we found AMBN in the basal portion of HERS of lower first molar in mice, but not at the tip. We designed and synthesized small interfering RNA (siRNA) targeting AMBN based on the mouse sequence. When AMBN siRNA was injected into a prospective mandibular first molar of postnatal day 10 mice, the root became shorter 10 days later. Furthermore, HERS in these mice revealed a multilayered appearance and 5-bromo-2'-deoxyuridine (BrdU) positive cells increased in the outer layers. In vitro experiments, when cells were compared with and without transiently expressing AMBN mRNA, expression of growth suppressor genes such as p21(Cip1) and p27(Kip1) was enhanced without AMBN and BrdU incorporation increased. Thus, AMBN may regulate differentiation state of HERS derived cells. Moreover, our results suggest that the expression of AMBN in HERS functions as a trigger for normal root formation.


Ameloblasts/cytology , Dental Enamel Proteins/genetics , Gene Expression Regulation, Developmental , Odontogenesis/genetics , Tooth Root/growth & development , Ameloblasts/metabolism , Animals , Animals, Newborn , Bromodeoxyuridine , Cell Differentiation , Cell Proliferation , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Cyclin-Dependent Kinase Inhibitor p27/genetics , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Dental Enamel Proteins/antagonists & inhibitors , Dental Enamel Proteins/metabolism , Enamel Organ/anatomy & histology , Enamel Organ/growth & development , Enamel Organ/metabolism , Gene Silencing , Mice , Mice, Inbred C57BL , Molar/anatomy & histology , Molar/growth & development , Molar/metabolism , Organ Culture Techniques , RNA, Small Interfering/genetics , Tooth Crown/anatomy & histology , Tooth Crown/growth & development , Tooth Crown/metabolism , Tooth Root/anatomy & histology , Tooth Root/metabolism
18.
Stem Cells ; 29(8): 1294-303, 2011 Aug.
Article En | MEDLINE | ID: mdl-21630378

Chronic pain conditions are difficult to treat and are major health problems. Bone marrow stromal cells (BMSCs) have generated considerable interest as a candidate for cell-based therapy. BMSCs are readily accessible and are easy to isolate and expand ex vivo. Clinical studies show that direct injection of BMSCs does not produce unwanted side effects and is well tolerated and safe. Here, we show that a single systemic (intravenous) or local injection (into the lesion site) of rat primary BMSCs reversed pain hypersensitivity in rats after injury and that the effect lasted until the conclusion of the study at 22 weeks. The pain hypersensitivity was rekindled by naloxone hydrochloride, an opioid receptor antagonist that acts peripherally and centrally, when tested at 1-5 weeks after BMSC infusion. In contrast, naloxone methiodide, a peripherally acting opioid receptor antagonist, only rekindled hyperalgesia in the first 3 weeks of BMSC treatment. Focal downregulation of brainstem mu opioid receptors by RNA interference (RNAi) reversed the effect of BMSCs, when RNAi was introduced at 5- but not 1-week after BMSC transplantation. Thus, BMSCs produced long-term relief of pain and this effect involved activation of peripheral and central opioid receptors in distinct time domains. The findings prompt studies to elucidate the cellular mechanisms of the BMSC-induced pain relieving effect and translate these observations into clinical settings.


Bone Marrow Transplantation , Mesenchymal Stem Cell Transplantation , Pain Management , Stromal Cells/transplantation , Animals , Antigens, CD/metabolism , Bone Marrow Cells/metabolism , Cell Shape , Male , Mesenchymal Stem Cells/metabolism , Myelencephalon/metabolism , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , RNA Interference , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/metabolism , Stromal Cells/metabolism , Tendon Injuries/therapy
19.
Eur J Pain ; 15(5): 467.e1-14, 2011 May.
Article En | MEDLINE | ID: mdl-21093329

It has been reported that the whisker pad (WP) area, which is innervated by the second branch of the trigeminal nerve, shows allodynia/hyperalgesia following transection of the mental nerve (MN: the third branch of the trigeminal nerve). However, the mechanisms of this extra-territorial pain induction still remain unclear. Glia and cytokines are known to facilitate perception of noxious input, raising a possibility that these non-neuronal elements are involved in the induction and spread of allodynia/hyperalgesia at non-injured skin territory. One day after MN transection, tactile allodynia/hyperalgesia developed on the ipsilateral WP area, which is in the non-injured skin territory. The tactile allodynia/hyperalgesia lasted for more than 56 days. In response to MN transection, astrocytes and microglia appeared to be in an activated state, and interleukin (IL)-1beta was up-regulated in astrocytes in the trigeminal subnucleus caudalis (Vc). Allodynia/hyperalgesia at WP area induced by MN transection was attenuated dose-dependently by IL-1 receptor antagonist IL-1ra (i.t., 0.05, 0.5, and 5 pg/rat). Fos-like immunoreactive (Fos-Li) neurons were observed in the Vc after non-noxious mechanical stimulation of the WP area in the rats with MN transection. Administration of IL-1ra also attenuated the number of Fos-Li neurons dose-dependently. Administration of a noncompetitive antagonist of NMDA receptors MK-801 (i.t., 5 µg/rat) reversed allodynia/hyperalgesia. IL-1 receptor type I (IL-1RI) was localized in Fos- and phospho NR1-immunoreactive neurons. These results suggest that IL-1beta in the Vc plays an important role in the development of extra-territorial tactile allodynia/hyperalgesia after MN transection.


Astrocytes/metabolism , Hyperalgesia/metabolism , Interleukin-1beta/metabolism , Microglia/metabolism , Trigeminal Caudal Nucleus/metabolism , Trigeminal Nerve Injuries , Animals , Antirheumatic Agents/pharmacology , Astrocytes/pathology , Disease Models, Animal , Dizocilpine Maleate/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Hyperalgesia/drug therapy , Hyperalgesia/pathology , Injections, Spinal , Interleukin 1 Receptor Antagonist Protein/pharmacology , Mandible/innervation , Microglia/pathology , Rats , Trigeminal Caudal Nucleus/pathology , Up-Regulation/physiology , Vibrissae/innervation
20.
Vaccine ; 28(27): 4362-8, 2010 Jun 17.
Article En | MEDLINE | ID: mdl-20438876

Bordetella parapertussis causes typical whooping cough, as does Bordetella pertussis. However, current commercial vaccines are ineffective against B. parapertussis. In an effort to develop vaccines that are effective in protecting against both B. pertussis and B. parapertussis, we examined the protective effects of vaccines prepared from whole-cells and from recombinant proteins derived from B. parapertussis in a mouse intranasal challenge model. We confirmed current pertussis vaccines did not induce protective immunity against B. parapertussis in the mouse model. A whole-cell vaccine prepared from B. parapertussis induced protective immunity against B. parapertussis but not against B. pertussis, suggesting a combination of a current pertussis vaccine with a whole-cell parapertussis vaccine might prevent whooping cough caused by both species of Bordetella. We also found that filamentous hemagglutinin was a protective antigen of B. parapertussis. Our observations should lead to the development of new pertussis vaccines that can control the two prevalent forms of whooping cough.


Bordetella parapertussis/immunology , Bordetella pertussis/immunology , Pertussis Vaccine/immunology , Agglutination Tests , Animals , Blotting, Western , Bordetella parapertussis/metabolism , Bordetella parapertussis/physiology , Bordetella pertussis/metabolism , Bordetella pertussis/physiology , Female , Mice , Mice, Inbred BALB C , Whooping Cough/immunology , Whooping Cough/prevention & control
...